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Abstract
Current lipidomic profiling methods rely mainly on MS to identify unknown lipids within a complex
sample. We describe a new approach, involving LC×MS/MS (liquid chromatography×tandem MS) analysis
of sphingolipids based on both mass and hydrophobicity, and use this method to characterize the SM
(sphingomyelin), ceramide and GalCer (galactosylceramide) content of hippocampus from AD
(Alzheimer's disease) and control subjects. Using a mathematical relationship we exclude the influence of
sphingolipid mass on retention time, and generate two-dimensional plots that facilitate accurate
visualization and characterization of the different ceramide moieties within a given sphingolipid class,
because related molecules align horizontally or vertically on the plots. Major brain GalCer species that
differ in mass by only 0.04 Da were easily differentiated on the basis of their hydrophobicity. The
importance of our method's capacity to define all of the major GalCer species in the brain samples is
illustrated by the novel observation that the proportion of GalCer with hydroxylated fatty acids increased
approximately 2-fold in the hippocampus of AD patients, compared with age- and gender-matched
controls. This suggests activation of fatty acid hydroxylase in AD. Our method greatly improves the clarity
of data obtained in a lipid profiling experiment and can be expanded to other lipid classes.
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Synopsis
Current lipidomic profiling methods rely mainly on mass spectrometry to identify unknown lipids
within a complex sample. We describe a new approach, involving LC×MS/MS analysis of
sphingolipids based on both mass and hydrophobicity, and use this method to characterize the
sphingomyelin (SM), ceramide, and galactosylceramide (GalCer) content of hippocampus from
Alzheimer’s Disease (AD) and control subjects. Using a mathematical relationship we exclude the
influence of sphingolipid mass on retention time, and generate two-dimensional plots that facilitate
accurate visualization and characterization of the different ceramide moieties within a given
sphingolipid class, because related molecules align horizontally or vertically on the plots. Major brain
GalCer species that differ in mass by only 0.04 Da were easily differentiated on the basis of their
hydrophobicity. The importance of our method’s capacity to define all of the major GalCer species in
the brain samples is illustrated with the novel observation that the proportion of GalCer with
hydroxylated fatty acids increased approximately two-fold in the hippocampus of AD patients,
compared to age- and gender-matched controls. This suggests activation of fatty acid hydroxylase in
AD. Our method greatly improves the clarity of data obtained in a lipid profiling experiment and can
be expanded to other lipid classes.
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Abbreviations
AD, Alzheimer’s Disease; GluCer, glucosylceramide; GalCer, galactosylceramide; HFA,
hydroxylated fatty acid; LC, liquid chromatography; MRM, multiple reaction monitoring; MS, mass
spectrometry; NFA, normal fatty acid; RT, retention time; SM, sphingomyelin; TIC, total ion
chromatogram.
INTRODUCTION
The sphingolipids are a diverse family of structural and signaling lipids that have a broad range of
functions in normal physiology and pathology [1, 2]. Altered sphingolipid metabolism has been
implicated in the pathology of cancer [2], cardiovascular diseases [3], type II diabetes [4], and
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neurodegenerative diseases such as Parkinson’s disease [5] and AD [6]. The common constituent of
all sphingolipids is the sphingoid base, which in mammals is most commonly 18-carbon sphingosine
or dihydrosphingosine. A family of six ceramide synthases catalyze the transfer of fatty acids to the
amine group of sphingosine or dihydrosphingosine, forming the central sphingolipid metabolite
ceramide (Figure 1a). The fatty acids vary in length from 14 to 26 carbons, may contain one or more
double bonds, and may be hydroxylated. These variations create significant structural and biophysical
heterogeneity within ceramides. Addition of different headgroups to the primary hydroxyl of
ceramides gives rise to the different classes of sphingolipids, which are all built on a ceramide lipid
“backbone”.
Ceramide is itself a signaling molecule that is frequently associated with execution of apoptosis [2],
but also plays a role in establishing epithelial cell polarity [7] and the formation of cell-cell junctions
[8]. The abundant plasma membrane lipid SM is formed by the transfer of a phosphatidylcholine
headgroup onto ceramide (Figure 1a). The interaction of SM with cholesterol gives rise to lipid rafts,
specialized regions of the plasma membrane where cell signaling platforms are formed. Alternatively,
glucose, galactose, or phosphate headgroups may be transferred onto ceramide, giving rise to lipid
mediators with distinct functions. GalCer may be sulfated (forming sulfatide), and both of these lipids
are major constituents of myelin. Accordingly, GalCer synthesis is critical for normal brain function
[9, 10].
The aim of this research project was to develop a two-dimensional (2D) sphingolipid profiling
approach, in which the lipids are separated and identified on the basis of both mass and
hydrophobicity. Sphingolipids in biological samples are usually quantified using Liquid
Chromatography-tandem Mass Spectrometry (LC-MS/MS). In general, a defined number of lipid
metabolites are quantified by running the mass spectrometer in Multiple Reaction Monitoring (MRM)
mode, in which a specific precursor and product ion mass are used to identify each metabolite of
interest, which is quantified relative to external standards [11, 12]. However, MRM assumes prior
knowledge about which lipids are present in a given extract. A more objective profiling approach can
be achieved by scanning for precursor ions within a defined mass range, whilst monitoring for product
ions that are characteristic of a particular lipid backbone, e.g. sphingosine (m/z 264) or
dihydrosphingosine (m/z 266) [12]. Lipids identified using this approach may then be quantified more
accurately in a follow-up MRM experiment. However, assigning a molecular structure to a given lipid
based only on its precursor and product masses is not always feasible, because a given mass can often
be assigned to two or more biologically relevant structures.
Incorporating an LC step prior to MS/MS improves sensitivity by removing interfering ions,
separating out different lipid components in the cell or tissue extract, and concentrating each lipid
species into a narrow elution time window. In theory, the incorporation of an LC column prior to MS
can also provide biochemical information that helps to definitively assign a structure to a given
precursor and product mass. However, LC is not used in mass scanning/profiling experiments, firstly
because column Retention Time (RT) is not informative unless referenced to structurally defined
standards; and secondly because in reverse phase chromatography of lipids with the same headgroup,
differences in mass conferred by different acyl chain lengths have a large impact on RT. To
effectively use RT in the characterization of unknown lipids from a lipid profiling experiment, we
first needed to develop a method in which RT is made independent of N-acyl chain length, and
therefore mass. To do this we adapted and modified a method that was used for separation of
hydrocarbons [13, 14] and fatty acid methyl esters [15, 16].
We describe here an LC×MS/MS approach (as distinct from an LC-MS/MS approach) for
characterization of sphingolipids in complex biological extracts that we refer to as Mass and Relative
Elution Time (MRET) profiling. After excluding the influence of mass on RT for any given class of
sphingolipid, the resulting 2D plots can be used to predict the number and position of double bonds
within the lipid tails, and the presence of functional groups such as hydroxyls, without any need for
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chemical derivatization of the lipids or the use of high resolution mass analyzers. We describe how
this approach can be used to collate the MS output of brain tissue extracts from twelve different
human subjects, forming 2D plots of the SM, ceramide, and GalCer content that also incorporate a
semi-quantitative measure of relative abundance for each distinct metabolite. These plots are an
informative and versatile way to visualize complex lipidomic data sets. Importantly, we show how
this approach allows us to distinguish between GalCer species that are structurally and biochemically
different, but can not be distinguished on the basis of precursor and product ion mass.
EXPERIMENTAL
Liquid Chromatography and Mass Spectrometry
LC-MS/MS was performed on a Thermo TSQ triple quadrupole mass spectrometer, operating in
positive ion mode, coupled to a 3 x 150 mm Agilent XDB-C8 column (5 micron pore size) on an
Accela UPLC system (Thermo). In both methods, lipids were separated using a binary gradient
program, at a flow rate of 0.5 mL/min: mobile phase A was 0.2% formic acid/2 mM ammonium
formate in water; mobile phase B was 0.2% formic acid/1 mM ammonium formate in methanol. The
HPLC gradient for separation of ceramide and GalCer was as follows: 0 min, 20:80 A/B; 2 min, 15:85
A/B; 3min, 10:90 A/B; 4 min, 1:99 A/B; 5 min 0:100 A/B; 18 min 0:100 A/B; 20 min 20:80 A/B. C18
chromatography was performed on a 2 x 150 mm Phenomenex C18 column (3 micron pore size). The
gradient employed was: 0 min, 10:90 A/B; 2 min, 0/100 A/B; 43 min, 0/100 A/B; 45 min, 10/90 A/B.
The HPLC gradient for separation of SM (on the C8 column) was: 0 min, 20:80 A/B; 2 min, 10:90
A/B; 3 min, 1:99 A/B; 19 min, 1/99 A/B; 20 min, 20:80 A/B; 22 min, 20:80 A/B.
Ceramide and GalCer were analyzed simultaneously by precursor ion scanning over the mass range
450 to 1050 Da, monitoring for m/z 262.0, 264.1, and 266.1 product ions at collision energy 30 eV.
For clarity this paper describes results derived primarily from the m/z 264 product ion scan. Scan time
was one second for each event (i.e. each scan was run every three seconds). SM species were detected
separately, monitoring for an m/z 184 product ion at collision energy 35 eV. For ceramide standards
run over a broad concentration range, from 8 nM to 8 µM (total 6 concentrations), in precursor
scanning mode, Coefficient of Variation (CV) in m/z of LC peaks ranged from 0.005 to 0.06, whilst
CV in RT ranged from 0.018 to 0.407. Variation in retention time between the start and the end of a
sequence of 18 samples (i.e. 6 hours apart) was less than 1% for three different GalCer standards:
d18:1/12:0, RT = 6.88 and 6.88 min; d18:1/18:0, RT = 8.42 and 8.36 min; d18:1/24:1, RT = 10.39
and 10.33 min. For lipid detection in MRM mode, the TSQ was set to monitor a list of events as
shown in Table 1, each with a scan time of 0.06 seconds. Note that mass accuracy for the Quantum
TSQ is ± 0.5 Da.
High mass accuracy analysis of GalCer species was performed using an LTQXL Orbitrap Mass
Spectrometer operating in positive [electrospray] mode, connected to an Accela liquid
chromatography system (Thermo Scientific). The gradient program, at flow rate 0.4 mL/min, was as
follows: 0 min, 20:80 A/B; 2.5 min, 15:85 A/B; 3.8min, 10:90 A/B; 5 min, 1:99 A/B; 6.5 min 0:100
A/B; 30 min 0:100 A/B; 32 min 20:80 A/B. Mass spectra were recorded in Fourier Transform full
scan mode, mass range 80 - 1100 Da, mass resolution 60000 (m/∆m, FWHM at 400 Da).
Lipid Extraction from Human Brain Tissue
Human brain tissues were obtained from the Sydney Brain Bank and the New South Wales Tissue
Resource Centre. Ethics approval for the current study was from the University of Wollongong
Human Research Ethics Committee (HE10/327). Tissue samples were obtained from brains of six AD
patients, clinically and pathologically defined using NIA-Reagan criteria, and six age- and gendermatched controls [17]. These 12 samples have been used in another, unrelated study [18]. Clinical
information for each case including gender, age at death, post-mortem interval (PMI), and clinical

	
  

3	
  

cause of death is provided in Table 2. Frozen brain tissue from the hippocampus and cerebellum was
pulverized over dry ice and stored at -80°C until required for analysis.
Lipids were extracted from approximately 10 mg frozen brain tissue, using a modification of the
single phase extraction method described by Bielawski et al [19]. A 1.5 mL mixture of ethyl
acetate:isopropanol:water (30:10:60, v/v/v) (solution A), together with 1.5 mL chloroform/methanol
(1:2) (solution B), was added to the frozen brain tissue in a 15 mL glass tube. A 50 µL cocktail of
internal standards was added, comprising 5 µM each of d18:1/17:0 ceramide, d18:1/12:0 SM, and
d18:1/12:0 GalCer. The brain tissue was further crushed with a dounce homogenizer, sonicated for 2 h
in a Unisonics FXP10M water bath and incubated, with occasional sonicating, for 10 h at 35 °C to
extract sphingolipids [12]. The extract was centrifuged for 10 min at 3700×g (25°C), and the
supernatant transferred to a clean glass tube. The residue was re-extracted with 1.5 mL solution A as
described above, then 1 mL chloroform/methanol (2:1). The supernatants from each extraction step
were combined, divided into two parts, then dried down in a Thermo SC210 Speedvac. One half of
the extract was reconstituted in 200 µL HPLC mobile phase (80:20 A/B), vortexed thoroughly, and
centrifuged at 3700×g for 5 min (25°C). The supernatant was transferred to an HPLC vial with 200
µL glass insert, and stored at –20°C until LC-MS/MS analysis of ceramide and GalCer/GluCer
content. The other half of the extract was further processed for SM analysis, exactly as described
previously [19]. Note that for SM preparation an alkaline hydrolysis step is included to remove
phosphatidylcholine, which is highly abundant and may interfere with SM analysis. Analytical
(HPLC) grade solvents were purchased from Merck. All lipid standards were purchased from Avanti
Polar Lipids, except for SM(d18:1/22:0), which was from Matreya LLC.
Data extraction and collation from multiple samples
LC-MS/MS data from each sample was converted to mzXML file format using ReAdW (version
4.3.1) [20] with default parameters. The data was then processed using in-house software: Mass
spectra were de-isotoped based on the detection of estimated mass-dependent isotope profiles. In this
process, the intensity of all isotopic peaks is combined into a single monoisotopic peak. Furthermore,
water loss events (-18±0.25 m/z) were also removed from each spectrum. Peaks were then detected in
each spectrum within the LC-MS/MS run. We defined a peak as ions with an intensity of greater than
2.5% of the base peak and with at least 10,000 ion counts. To eliminate redundancy, all peaks with a
similar mass (±0.25 m/z) and retention time (±0.5 minutes) arising from the same transition events
across the chromatogram were culled, with the most intense peak within each mass and retention time
window retained. To determine the abundance of a peak within a sample, the selected ion
chromatogram is computed with a mass window of ± 0.25 m/z and smoothed using the SavitzkyGolay filter [21] before the area under the chromatogram was calculated. This procedure results in a
final list of peaks and their corresponding abundance for each selected reaction monitoring event. For
MRM experiments, the precursor mass was used directly from each monitored event.
For sample comparison, peak lists generated from each sample were further compiled to generate a
list of peaks with aligned mass and retention times. The alignment process is based on the use of mass
and retention time windows (± 0.5 m/z and ± 0.5 min, respectively). For the SM analysis, the retention
time window was increased to ± 1.0 min to accommodate broader elution peaks, and to account for
chromatographic variation between analyses which were performed over several days. We did not
find it necessary to apply sophisticated non-linear alignment procedures [22].
This software tool is implemented using C++ and is available to the research community as a web
resource, located at http://www.cancerresearch.unsw.edu.au/crcweb.nsf/page/lipidms. Source
code will be made available to non-commercial users upon request.
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The RT vs m/z data for d18:1/(12:0, 14:0, 16:0, 18:0, 20:0, 22:0, and 24:0) ceramide standards was
fitted to a centered second order polynomial equation, given by y = 9.423 + 0.0353(x – 566.5) +
0.000133(x - 566.5)2 using GraphPad PRISM (R2 = 0.9994). For C18 chromatography, the
relationship between m/z and RT was also quadratic, given by y = 9.610 + 0.09921(x – 576.7) +
0.0005569(x – 576.7)2; R2 = 0.9987. This equation was then used to derive a theoretical RT for all m/z
values. The theoretical RT was subtracted from the observed RT, yielding the relative RT (which is
approximately 0 for all points used to fit the curve). There were insufficient commercially available
GalCer and SM standards to derive the RT vs m/z relationship. We therefore extracted the m/z and RT
for GalCer and SM bearing saturated N-acyl chains with an even number of carbons ranging from 16
to 26 in length (i.e. d18:1/16:0 through to d18:1/26:0), in the collated hippocampus extracts. The RT
values were compared to those observed with the commercially available standards (d18:1/16:0 and
d18:1/18:0 for GalCer; d18:1/16:0, d18:1/22:0, and d18:1/24:0 for SM), to confirm that the RT values
were accurate to within 0.1 min. The six data points obtained from the hippocampus extracts were
then fitted to a centered second order polynomial (R2 = 0.9992 and 0.9993, for GalCer and SM,
respectively) and relative RT values were obtained by fitting all observed m/z values to the equation
and subtracting the resultant theoretical RT from the observed RT, as described above. Peak areas for
each lipid identified were expressed as ratios to the relevant internal standard (d18:1/12:0 SM,
d18:1/17:0 ceramide, or d18:1/12:0 GalCer), and normalized for the amount of starting brain tissue.
For peaks identified by the m/z 264 product ion, the data was normalized separately to both ceramide
and GalCer internal standards, yielding two distinct intensity plots.
Ceramide and GalCer content (in pmoles/mg tissue) was calculated from standard curves constructed
with available synthetic standards. In the case of GalCer, standards for d18:1/18:0 and d18:1/24:0
GalCer were used to quantify long chain (C16 – C20) and very long chain (C22 – C26) GalCer,
respectively.
Statistical Analysis
Two-tailed t-tests were used to compare lipid levels or ratios between normal and AD hippocampus,
and between normal hippocampus and normal cerebellum. Equal variances were not assumed.
RESULTS
Mass and Relative Elution Time (MRET) profiling approach
In this article we use the LipidMAPS (www.lipidmaps.org) nomenclature system for sphingolipids,
represented as “Lipid Class(length:double bonds of sphingoid base chain/length:double bonds of Nacyl chain)”, e.g. SM(d18:1/24:0) refers to sphingomyelin with an 18-carbon sphingosine backbone
with one double bond, and a 24-carbon N-acyl chain with no double bonds (Figure 1a).
The aim of this project was to create a system that facilitates the use of column RT, as well as
precursor and product masses, for characterising the sphingolipid content of complex biological
extracts. To define a relationship between mass and RT, we first used a mixture of ceramide
standards. We observed that the elution, from a C8 column, of ceramide standards ranging in N-acyl
chain length from 12 to 24 carbons follows a quadratic relationship under isocratic elution conditions
(100% methanol) (Figure 1b). Using this equation, we calculated the theoretical RT for each of a
mixture of ceramide and dihydroceramide standards. The difference between observed and theoretical
RT was termed “relative RT”, and plotted against m/z (Figure 1c). Ceramides differentiated only by
the length of their N-acyl chain align horizontally, because they have an equivalent relative RT.
Ceramides with an identical number of carbons but differing in the number of acyl chain double
bonds align vertically. Ceramides with a 2-hydroxyl group in their N-acyl chain, referred to as
Hydroxylated Fatty Acid (HFA) ceramides, are less hydrophobic and consequently have a more
negative retention time relative to that expected for a Normal (i.e. non-hydroxylated) Fatty Acid
(NFA) ceramide of equivalent mass. We next sought to determine if this approach would aid in the
identification and characterization of sphingolipids in a complex biological extract.
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Profiling the SM, Cer, and HexCer content of human brain tissue
De novo sphingolipid synthesis gives rise to ceramides, which are then used to produce SM, GalCer,
and GluCer (Figure 1a). GluCer and GalCer are geometric isomers, and therefore can not be resolved
on the basis of mass or affinity for the C8 column. GalCer is one of the major brain lipids, estimated
to comprise 20 – 25 % of the total lipid content of myelin [23]. It is approximately 200-fold more
abundant in the human brain than GluCer [24, 25], and we therefore refer to the human brain
hexosylceramides that we have detected as GalCer, noting that this analyte is predicted to contain
approximately 0.5 mol % GluCer.
We employed precursor ion scanning, using defined product ions with m/z 264 and 184, to identify
the ceramide, GalCer, and SM species present in extracts of cerebellum and hippocampus from six
AD patients, and six age- and gender-matched control subjects. The ion with m/z 264 is produced by
sphingolipids with a d18:1 sphingosine backbone, whilst the ion with m/z 184 is the choline
headgroup of SM. The LC-MS/MS data was processed as described in experimental procedures to
generate a summary table showing m/z and RT values for all the distinct peaks in a set of samples, and
the corresponding peak area (i.e. ion abundance) for that particular metabolite in each individual
sample.
The principle SM, ceramide, and GalCer components in the cerebellum and hippocampus extracts are
shown in Figure 2, in which the mean peak area (n = 6) relative to other lipids is represented by the
size of the bubble. A colour gradient is used to show abundance in AD, relative to control brain
extracts. Lipids with no double bonds in their N-acyl chain, but differing in the number of N-acyl
chain carbons align horizontally with a relative RT of approximately 0. Lipids with an identical
number of carbons but differing degrees of unsaturation align vertically, as exemplified by the
alignment of ions on the SM maps with m/z 811.7, 813.7, and 815.7, representing d18:1/24:2,
d18:1/24:1, or d18:1/24:0 SM, respectively (Figure 2a). To confirm the identity of these products as
SM species with a sphingosine backbone, we verified that both 184 (phosphatidylcholine) and 264
(sphingosine backbone) m/z fragments were produced at the same column RT in a single sample run,
after fragmentation of the m/z 731.6, 813.7, and 815.7 [SM(d18:1/18:0), SM(d18:1/24:1), and
SM(d18:1/24:0)] precursor ions (collision energy 35 eV). Similarly, GalCer species with C24:1,
C25:1, and C26:1 N-acyl chains (horizontal row at -1.0 to -1.1 min) align vertically with their C24:0,
C25:0, and C26:0 counterparts (Figure 2c).
We identified two horizontal series of lipids whose mass corresponds to GalCer with a hydroxylated
fatty acid (i.e. HFA-GalCer; +16 Da), and 0 or 1 double bonds in their N-acyl chain, indicated by long
arrows in Figure 2c. These lipids cluster in terms of m/z and RT with other GalCer species, but as
would be expected for HFA-GalCer, they elute from the C8 column earlier than their NFA
counterparts, with relative RT of -1.1 to -1.4 (22:0, 23:0, 24:0, 25:0, 26:0 N-acyl chains) and -1.9 to 2.4 (23:1, 24:1, 25:1, 26:1 N-acyl chains), providing important evidence to confirm our prediction of
their structure based on mass. Note that the shifted RT of these ions relative to their NFA counterparts
also confirms that they are not oxidized GalCers, created during electrospray ionization. As expected,
we observed no mass corresponding to the hydroxylated (m/z + 16) version of the GalCer(d18:1/12:0)
internal standard. HFA lipids were observed only in GalCer, reflecting the strong preference of the
enzyme UDP-galactose ceramide galactosyltransferase for HFA-ceramide substrates [26-28].
The importance of using relative RT for lipid identification is emphasized by the presence of two
distinct peaks for m/z 826.7 indicated by arrowheads in Figure 2c. Using the online metabolomic
search tool METLIN, this metabolite is identified as GalCer(d18:1/25:0). In accordance with that
prediction, one of the peaks with m/z 826.7 has a relative RT of -0.07 and sits on the y-axis. However,
the second peak has a relative RT of -2.17, and based on its position on the 2D plot, we predict that
this ion is HFA-GalCer(d18:1/24:1). It aligns horizontally with 840.7 and 854.7 Da ions, which
correspond by mass to HFA-GalCer with 25:1 and 26:1 N-acyl chains. Because GalCer(d18:1/25:0)
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and HFA-GalCer(d18:1/24:1) are separated in mass by only 0.04 Da and generate the same product
ion (m/z 264), they would probably have been misconstrued as the same lipid, using any mass
spectrometer other than a very high mass accuracy instrument. To further verify that these are indeed
distinct GalCer species, we checked their mass and relative elution pattern on an LTQXL Orbitrap:
m/z for the earlier eluting peak, predicted to be HFA-GalCer(d18:1/24:1), was 826.6741 (predicted
mass 826.6767, machine accuracy -3.13 ppm); whilst for the later eluting peak, predicted to be NFAGalCer(d18:1/25:0), measured m/z was 826.7114 (predicted mass 826.7130, machine accuracy -1.99
ppm).
Another example further illustrates the importance of using relative RT in the identification of
structure: in the ceramide plots an ion with m/z 664.6, indicated by an arrowhead in Figure 2e, could
be either Cer(d18:1/25:0) or HFA-Cer(d18:1/24:1). Even in the absence of external standards for
either of these lipids, we were readily able to identify this lipid as Cer(d18:1/25:0) based on its
relative RT of 0.03 min.
Decreased total GalCer and increased HFA:NFA GalCer ratio in Alzheimer’s Disease brains
Visual inspection of Figure 2f suggested that NFA-GalCer content declined by more than 2-fold in the
hippocampus of AD patients, whilst HFA-GalCer was less affected. The reduction in GalCer content
per mg tissue in AD hippocampus was in itself not statistically significant, due to the large standard
deviations that are to be expected with human subjects (P = 0.06). However, when normalised to the
SM content in each sample (thereby offsetting the variation in total lipid content between samples),
the decline in GalCer levels in AD hippocampus was statistically significant (Figure 3a). Note that
total hippocampus SM content was unchanged (control: 1.12 ± 0.25 nmoles/mg tissue; AD: 1.18 ±
0.24 nmoles/mg tissue (Mean ± Std Dev)). HFA-GalCer was significantly increased as a proportion of
total GalCer (Figure 3b), and this altered HFA:NFA GalCer ratio was seen for all GalCer species
(Figure 3c), suggesting either that fatty acid hydroxylase activity is increased or that catabolism of
HFA-GalCer is slower than for NFA-GalCer in AD hippocampus. The only HFA-ceramide that could
be detected was Cer(d18:1/24:0), which was present at detectable levels in all six of the AD
hippocampus samples, but only one of the control samples. Having identified the major GalCer
species present in human brain extracts using precursor ion scanning, we employed a more
quantitative MRM approach to further test the utility of our relative elution time method and confirm
the altered HFA:NFA-GalCer ratio in AD hippocampus.
Application of the relative elution time method to Multiple Reaction Monitoring experiments
Table 1 shows the MRM events we used and the specific species that we anticipated would be
identified with each event. Figure 4a shows the total ion chromatogram for a single hippocampus
sample, together with extracted ion chromatograms for the events with precursor ion m/z 826.7 or
840.7. As described above, the two peaks observed for the m/z 826.7 ion are NFA-GalCer(d18:1/25:0)
and HFA-GalCer(d18:1/24:1), which are separated in mass by only 0.04 Da. There are no synthetic or
purified standards for these lipids, so they can only be differentiated either through further
fragmentation studies, or on the basis of their RT relative to known standards, as illustrated in Figure
4b. Similarly, two of the peaks observed in the m/z 840.7 event (Figure 4a) may be identified, based
on their relative RT, as NFA-GalCer(d18:1/26:0) and HFA-GalCer(d18:1/25:1). The third, middle
peak is a heavy isotope of NFA-GalCer(d18:1/26:1), which is removed by de-isotoping the data.
As was observed with precursor ion scanning, there was a reduction in the NFA-GalCer content of
AD hippocampus, compared to the controls (Figure 4b and Table 1). All NFA-GalCers were reduced
in abundance, in AD compared to control hippocampus samples, and there were statistically
significant reductions in a number of very long chain ceramides (Table 1). In contrast, HFA-GalCer
content did not decrease. Rather, there was a slight increase in total HFA-GalCer content, and
calculation of the HFA-GalCer content as a proportion of total GalCer confirmed the statistical
significance of this difference between control and AD subjects (Figure 4c).
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Applicability of the relative elution time method to C18 chromatography
To demonstrate the portability of our method to other column types, we ran our mixture of ceramide
and dihydroceramde standards and one of the hippocampus extracts on a C18 column, which are
commonly used in sphingolipid analyses. As expected, the quadratic relationship between column RT
and mass was also seen with this column (eluting under isocratic conditions with 100% methanol)
(Figure 5a). The same relationship between RT and mass is observed when the ceramides are eluted
with 90% isopropanol/10% water (data not shown). The pattern of hippocampal galactosylceramides
eluting from the C18 column was very similar to that observed with a C8 column. Column RT for
GalCer species with a sphingosine base and a saturated N-acyl chain (i.e. d18:1/N:0) followed a
quadratic relationship with respect to mass, and after application of our RT transform the NFAGalCer and HFA-GalCer species form distinct rows on a plot of relative RT vs m/z (Figure 5b).
DISCUSSION
The lipid profiling approach that we describe represents a significant improvement over current
methods because the physicochemical characteristics of the lipids facilitate their identification. These
characteristics may be critically important in resolving structurally different lipids that have almost
identical mass and are within the same broad functional class, as in the example we present with
NFA-GalCer(d18:1/25:0) and HFA-GalCer(d18:1/C24:1). Approaches that employ the
physicochemical characteristics of lipids, including multi-dimensional mass spectrometry (MDMS)based shotgun lipidomics [29] and TLC-MALDI [30], have been employed to separate different
classes of lipids before MS analysis, but not to separate lipids within the same structural class. In fact,
shotgun approaches such as MDMS are unable to resolve HFA- and NFA-GalCers that have almost
identical mass [31]. The relative RT method that we describe herein greatly aids in the identification
of lipids within the same structural class and in determining whether a particular metabolite belongs to
a particular lipid class. We note that current published protocols for comprehensive sphingolipidomic
analysis do not incorporate monitoring of HFA-GalCer [11, 12]. Although we employed a high mass
accuracy Orbitrap instrument to verify our method, the use of these instruments is inherently more
complex and they can not be set to perform precursor ion scans with defined product ions or multiple
reaction monitoring.
In addition to improving the accuracy of lipid structure characterization, the resultant 2D plots greatly
improve visualization of the data, when compared to a tabulated list. A recent review identified
visualization of data as one of the key issues in sphingolipidomic systems analysis [1]. To illustrate
this point, a 2D map of the MS intensity output using precursor ion scanning over the m/z range 680 –
900 (product ion m/z 264), from a single cerebellum sample before and after RT transformation is
shown in Supplementary Figure 1. Plotting distinct LC peaks (as in Figure 2) rather than the raw
intensity data (Supplementary Figure 1) improves the visual appearance of the data and makes it much
simpler to present the mean of multiple samples, thereby improving our capacity to draw meaningful
inferences from the data. Using our method, we could readily visualize the GalCer content of brain
samples taken from AD patients and normal controls. Synthetic or purified standards are not available
for most of the GalCer species shown in Figures 2 and 4, which makes the unambiguous assignment
of lipid structure based on the most commonly employed MS1 or MS2 approaches impossible. More
detailed analyses of the fragmentation pattern of individual lipids generally reveals the structure, but
this is not always the case and this approach often necessitates chemical derivatization of lipids prior
to MS analysis or the use of more reactive collision gases [32]. Using our approach, chemical
derivatization is not necessary and important biochemical information can be obtained for many lipids
simultaneously.
It is well established in the literature that precursor ion scanning, because of its reduced duty cycle, is
less quantitative than MRM approaches. However, we believe that precursor ion scans such as we
have used in this study are an important tool for establishing the principal lipids of interest for
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subsequent MRM experiments, and are a valid approach for establishing trends in the data. We found
that the principal trends observed using precursor ion scanning - a reduction in total GalCer content
and an increase in HFA-GalCer content as a proportion of the total GalCer content - were reproduced
in MRM mode which, as expected, yielded a greater linear range for absolute quantification. Although
ceramide 1-phosphates were not abundant in the brain tissues analyzed in this study, we have found
that the precursor ion scan with product ion m/z 264 used in this study is also sufficient to detect gross
changes in ceramide 1-phosphate content in cultured cells. We have been unable to detect the
principle dihydroceramide species using precursor ion scanning coupled to a product ion m/z of 266,
due to their low abundance and their relatively poor fragmentation to the m/z 266 backbone ion
(compared to the m/z 264 ion characteristic of sphingosine). However, we have found that
sphingolipids bearing a sphinga-2,4-diene backbone can readily be identified with a precursor scan
coupled to a product ion with m/z 262 (Supplementary Figure 1c) [33].
This is the first study to demonstrate an increase in the ratio of HFA-GalCer:NFA-GalCer in the
brains of AD patients. This change was accompanied by an overall decline in hippocampal GalCer
content, although not statistically significant in this study. The loss of GalCer in AD is in agreement
with older literature employing thin layer chromatography techniques [34, 35]. These changes were
observed in the hippocampus but not the cerebellum, in accordance with the pathology of AD:
hippocampal atrophy associated with a pronounced loss of pyramidal neurons is a defining feature of
AD, whilst the cerebellum is much less affected [36, 37]. More recent mass spectrometry analysis has
shown a decline in sulfatide content, in the absence of any decline in GalCer content, in various
regions of the cerebral cortex of AD subjects [38]. We note that these authors did not examine
changes in the hippocampus, whilst we did not examine any frontal or temporal cortex tissue. In
future studies, we aim to investigate the changes to these myelin sphingolipids using a much larger
cohort of patient samples.
We found HFA-GalCer to comprise approximately 50% of total GalCer in the cerebellum, and 20% in
the hippocampus of control subjects. Previous studies have reported that HFA-GalCer comprises
approximately half of total GalCer in myelin [39, 40]. Whilst very long chain ceramides (those with
>24 carbon N-acyl chains) declined in abundance in AD hippocampus, we observed an increase in the
only detectible HFA-ceramide, d18:1/24:0 (Table 1). In precursor scanning mode, HFACer(d18:1/24:0) was detected in all six AD hippocampus samples, but only one of the control
hippocampus samples. These results suggest increased fatty acid hydroxylase activity in AD. Barrier
et al [41] have very recently reported an increase in the ratio of HFA-ceramide:NFA-ceramide in the
cerebral cortex, in a mouse model of AD (APPSL/PS1 Ki). Interestingly, the increased ratio was only
observed in female mice. Our human cohort is too small to draw firm conclusions on sex-related
differences (see Table 2), but we note that when separated on the basis of gender, the HFA:NFA
GalCer ratio was significantly different between AD and control females (P = 0.0006), but not males.
In summary, a rapidly growing body of literature is now highlighting the importance of lipid
metabolites to cell signaling and pathophysiological processes. We present a new method that
improves the combined use of liquid chromatography and mass spectrometry to create a 2D analysis
of sphingolipids in a complex biological extract. The data transform that we apply can in theory be
applied to any chromatography in which the separation of different lipids within the same functional
class is dependent on the length of the lipid tails. The increased capacity of our approach to
objectively profile lipid content is illustrated with the new findings we describe regarding changes in
the sphingolipid content in the brains of AD patients. Our approach can be applied to other classes of
lipids, and its application in lipidomics will improve the discovery process.
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TABLES
Table 1. Abundance of individual ceramide and GalCer species in human hippocampus
extracts, as determined by MRM.
Lipids possess non-hydroxylated fatty acid (NFA) chains, unless HFA is prefixed to the name.
Different lipids sharing the same precursor mass were differentiated on the basis of relative RT. The
product m/z was set at 264.1 for all events, whilst collision energy was set at 30 eV for ceramides and
35 eV for GalCers. Note that internal standards Cer(d18:1/17:0) and GalCer(d18:1/12:0) were
detected with precursor m/z 552.7 and 644.6, respectively. Units of abundance are pmoles lipid/mg
tissue, and values shown are the mean ± standard deviation of six patient samples. Dash indicates that
lipid was not quantified due to very low abundance. Asterisk (*) indicates a statistically significant
difference (P < 0.05) between control and AD hippocampus, as determined by two-tailed t-test.
Lipid

Precursor m/z

Cer(d18:1/16:0)
Cer(d18:1/18:1)
Cer(d18:1/18:0)
Cer(d18:1/20:0)
Cer(d18:1/22:0)
Cer(d18:1/23:1)
Cer(d18:1/23:0)
Cer(d18:1/24:1)
Cer(d18:1/24:0)
Cer(d18:1/25:1)
Cer(d18:1/25:0)
HFA-Cer(d18:1/24:0)
Cer(d18:1/26:1)
Cer(d18:1/26:0)

538.6
564.6
566.7
594.7
622.7
634.7
636.7
648.8
650.8
662.8
664.8
666.8
676.8
678.8

Total Ceramide
GalCer(d18:1/16:0)
GalCer(d18:1/18:1)
GalCer(d18:1/18:0)
HFA-GalCer(d18:1/18:1)
HFA-GalCer(d18:1/18:0)
GalCer(d18:1/20:1)
GalCer(d18:1/20:0)
HFA-GalCer(d18:1/20:1)
HFA-GalCer(d18:1/20:0)
GalCer(d18:1/22:1)
GalCer(d18:1/22:0)
GalCer(d18:1/23:1)
GalCer(d18:1/23:0)
HFA-GalCer(d18:1/22:1)
HFA-GalCer(d18:1/22:0)
GalCer(d18:1/24:1)
GalCer(d18:1/24:0)
HFA-GalCer(d18:1/23:1)

	
  

700.7
726.7
728.7
742.7
744.7
754.7
756.7
770.7
772.7
782.7
784.7
796.7
798.7
798.7
800.7
810.7
812.7
812.7

Abundance Control
Hippocampus
0.30 ± 0.15
6.44 ± 2.46
0.12 ± 0.033
0.10 ± 0.040
0.097 ± 0.042
2.81 ± 1.11
0.27 ± 0.14
0.55 ± 0.27
0.043 ± 0.026
0.0089 ± 0.0084
0.25 ± 0.096
-

Abundance AD
Hippocampus
0.52 ± 0.23
6.43 ± 4.31
0.18 ± 0.10
0.098 ± 0.022
0.060 ± 0.022
1.52 ± 0.83*
0.15 ± 0.068
0.23 ± 0.15*
0.015 ± 0.0098*
0.0139 ± 0.0062
0.081 ± 0.051*
-

10.96 ± 3.14

9.28 ± 4.92

3.00 ± 1.82
184.5 ± 89.5
7.38 ± 3.25
10.97 ± 3.73
6.87 ± 2.73
39.95 ± 13.83
22.91 ± 10.24
64.11 ± 20.91
23.48 ± 9.99
685.3 ± 291.1
247.5 ± 85.6
-

2.08 ± 1.31
106.2 ± 120.9
5.98 ± 3.68
7.16 ± 8.59
4.06 ± 4.65
26.82 ± 24.85
11.51 ± 12.36
40.89 ± 27.20
28.21 ± 9.06
387.9 ± 366.6
155.8 ± 106.8
-
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HFA-GalCer(d18:1/23:0)
GalCer(d18:1/25:1)
GalCer(d18:1/25:0)
HFA-GalCer(d18:1/24:1)
HFA-GalCer(d18:1/24:0)
GalCer(d18:1/26:1)
GalCer(d18:1/26:0)
HFA-GalCer(d18:1/25:1)
HFA-GalCer(d18:1/25:0)
HFA-GalCer(d18:1/26:1)
HFA-GalCer(d18:1/26:0)
Total Galcer
Total NFA-GalCer
Total HFA-GalCer

	
  

814.7
824.8
826.8
826.8
828.8
838.8
840.8
840.8
842.8
854.8
856.8

34.06 ± 18.47
202.4 ± 84.7
85.77 ± 28.99
168.1 ± 70.0
53.80 ± 28.07
208.5 ± 57.9
30.21 ± 7.70
19.81 ± 12.67
14.70 ± 8.28
21.55 ± 10.65
9.57 ± 3.38

47.20 ± 18.74
122.1 ± 89.7
56.96 ± 43.49
142.6 ± 50.1
67.57 ± 33.13
126.5 ± 66.1*
20.02 ± 17.30
32.22 ± 16.82
21.17 ± 8.54
40.33 ± 23.28
8.50 ± 3.79

2145 ± 741
1792 ± 613
352.5 ± 148.6

1462 ± 888
1068 ± 860
393.7 ± 135.5
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Table 2. Patient brain samples used in this study
PMI, post-mortem interval; NFT, neurofibrillary tangle
ID#
1
2
3
4
5
6
7
8
9
10
11
12

	
  

age
85
79
93
78
69
82
83
84
83
73
83
69

gender
female
male
female
female
male
male
male
female
female
male
female
male

PMI
(hrs)
23
8
21
11
13.5
23.5
25
6
3
16
4
3

cause of death
pneumonia
pulmonary embolism
cardiac failure
respiratory failure
myocardial infarction
multiple organ failure
cerebrovascular accident
aspiration pneumonia
uraemia
bronchopneumonia
circulatory collapse
colon cancer
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disease
duration
(yrs)
0
0
0
0
0
0
5
13
7
11
9
5

Braak NFT
stage [37]
0
0
0
0
0
0
stage VI
stage VI
stage V
stage VI
stage V
stage VI

FIGURE LEGENDS	
  
Figure 1. Two dimensional separation of ceramide standards according to mass and
hydrophobicity. (a) Structure and biochemical relationship of SM, ceramide, and GalCer. (b) Plot of
RT against m/z for a mixture of 16 different ceramide (Cer) and dihydroceramide (dhCer) standards,
as analysed by LC-MS/MS (10 pmole each). Lipids were separated on a C8 column and individual
species were identified by precursor ion scanning, monitoring for 264 and 266 Da product ions, at 30
eV. The curve is a centered second order polynomial, fitted to the following 7 standards: d18:1/12:0
(C12:0 Cer), d18:1/14:0 (C14:0 Cer), d18:1/16:0 (C16:0 Cer), d18:1/18:0 (C18:0 Cer), d18:1/20:0
(C20:0 Cer), d18:1/22:0 (C22:0 Cer), and d18:1/24:0 (C24:0 Cer). The other standards shown are:
d18:0/16:0 (C16:0 dhCer), d18:0/18:0 (C18:0 dhCer), d18:0/24:0 (C24:0 dhCer), d18:0/18:1 (C18:1
dhCer); d18:0/C24:1 (C24:1 dhCer); d18:1/18:1 (C18:1 Cer); d18:1/24:1 (C24:1 Cer); d18:1/18:0(2OH) (C18:0 HFA-Cer) and d18:1/24:0(2-OH) (C24:0 HFA-Cer). (c) Relative RT plotted against m/z
for all 16 standards. The identity of each standard is indicated on the graph. Note the vertical
alignment of standards with equivalent or almost equivalent mass, but a different number or position
of double bonds, indicative of separation based on hydrophobicity.
Figure 2. 2D plots of sphingolipid content in cerebellum and hippocampus: comparison of
control to AD brains. SM (a and d), ceramide (b and e), and GalCer (c and f) content of cerebellum
(a-c) and hippocampus (d-f). Each bubble represents a distinct ion peak on a plot of relative RT vs
m/z, and the size of the bubble is indicative of peak area after adjusting for internal standard recovery
and mass of homogenized tissue. Bubble sizes shown (i.e. adjusted peak areas) are the mean of six
samples, and for clarity in presentation, the sizing of the bubbles is normalized within each functional
class, i.e. SM, Cer and GalCer. The colour gradient indicates intensity of that metabolite in AD
samples (mean of 6), relative to control (mean of 6). Red: increased in AD; Blue: decreased in AD
brains. Relative RT was derived by transformation of RT for each corresponding m/z, relative to SM,
ceramide or GalCer with saturated N-acyl chains, as described in experimental procedures. C16, C18,
C20, C22, C24, and C26 refer to the length of N-acyl chains, as determined by mass and referenced to
external standards. Horizontal arrows show rows of HFA-GalCer species. Arrowheads in (c) indicate
the position of two distinct bubbles with an m/z of 826.7, which are GalCer(d18:1/25:0), at Relative
RT = 0; and HFA-GalCer(d18:1/24:1), at Relative RT = -2.2. Arrowhead in (e) indicates position of
Cer(d18:1/25:0).
Figure 3. Decreased GalCer and increased GalCer hydroxylation in AD hippocampus. (a) Total
GalCer content is expressed relative to total SM content in each of the brain samples. Horizontal bars
show the mean (n = 6). (b) Scatter plots showing total HFA-GalCer peak area, as a proportion of total
(HFA-GalCer + NFA-GalCer) peak area. (c) HFA-GalCer peak area, as a proportion of total (HFAGalCer + NFA-GalCer) peak area, for each different N-acyl chain length. Values are mean ± standard
error (n = 6). P values were derived from unpaired, two-tailed t-tests.
Figure 4. Use of relative elution time to confirm identity of GalCer species in MRM. (a) Total Ion
Chromatogram (TIC) and extracted chromatograms for the m/z 826.7 and 840.7 events, for a
hippocampus extract from a control patient analysed in MRM mode (events shown in Table 1). (b)
Relative RT vs m/z plot showing GalCer peaks detected in MRM mode. Bubbles illustrate the relative
abundance of each metabolite in all six control hippocampus extracts, and colour gradient describes
the abundance of each metabolite in the six AD, relative to the control, hippocampus extracts. (c)
HFA-GalCer as a proportion of total GalCer (HFA + NFA), for each of the control (n = 6) and AD (n
= 6) hippocampus samples. P value was derived from a two-tailed t-test.
Figure 5. Application of relative elution time method with a C18 chromatography column. (a)
Elution pattern for a mixture of ceramide standards eluted from a C18 column under isocratic
conditions (100% methanol); (i) shows absolute RT; whilst (ii) shows relative RT. Using a C18
column, the relationship between m/z and RT fits a quadratic equation. (b) Relative RT vs m/z plot of
the GalCer content in a control hippocampus extract, using a C18 chromatography column.
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